论文部分内容阅读
目的观察伊立替康(CPT-11)联合卡铂(CBP)方案(IC)治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法 46例经病理学或细胞学确诊的晚期NSCLC患者,接受CPT-11 50 mg/m~2,d_1、8静脉滴注;卡铂按Chatelut公式AUC=5,d_1静脉滴注,21 d为1个周期。至少化疗2个周期后评价客观反应率、疾病控制、无进展生存、总生存及不良反应。结果全组部分缓解(PR)16例,病情稳定(SD)12例,疾病进展(PD)18例,有效率(RR)34.8%,疾病控制率(DCR)60.9%,中位无进展生存时间(PFS)5.8个月,中位总生存时间(OS)11.6个月,主要不良反应为3~4级粒细胞减少、血小板减少、恶心呕吐、迟发型腹泻、脱发。结论 CPT-11联合CBP治疗NSCLC疗效确切,患者对不良反应耐受性较好。
Objective To observe the curative effect and adverse reactions of irinotecan (CPT-11) combined with carboplatin (ICC) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 46 patients with advanced NSCLC confirmed by pathology or cytology received intravenous infusion of CPT-11 50 mg / m ~ 2 and d_1,8. Carboplatin was given by the Chatelut formula AUC = 5, 1 cycle. Objective response rates, disease control, progression-free survival, overall survival and adverse reactions were evaluated after at least 2 cycles of chemotherapy. Results There were 16 cases of partial remission (PR), 12 cases of stable disease (SD), 18 cases of disease progression (PD), the effective rate was 34.8%, the disease control rate was 60.9%, the median progression-free survival time (PFS) of 5.8 months. The median overall survival time (OS) was 11.6 months. The major adverse reactions were grade 3 to 4 neutropenia, thrombocytopenia, nausea and vomiting, delayed diarrhea and hair loss. Conclusion CPT-11 combined with CBP treatment of NSCLC exact effect, patients with better tolerance to adverse reactions.